Astellas, Amgen to pay $124.75M for False Claims Act violations
By 
Jaclyn Jaeger2019-04-26T20:03:00
Pharmaceutical companies Astellas and Amgen will pay a total of $124.75 million to resolve allegations that they violated the False Claims Act by illegally paying the Medicare co-pays for their own high-priced drugs.
More from Regulatory Enforcement
-
ArticleNursing home chain and former CEO pay $146M each for federal health fraud
A New Jersey and Midwest nursing home chain, and its former chief executive, must pay more than $146 million each for extensive health care fraud for engaging in widespread fraud related to Medicare and Medicaid.
-
News BriefU.S. Treasury faces new pressure over unreleased Epstein bank records
The release of thousands of emails written by Jeffrey Epstein has sparked a political storm. One Democratic Senator is ramping up pressure for the U.S. Treasury to also disclose the deceased financier’s bank records.
-
ArticleHorizon Blue Cross Blue Shield pays $100M to settle state false claims allegations
Horizon Blue Cross Blue Shield of New Jersey has agreed to pay $100 million to settle allegations that its 2020 contract with the state was fraudulent, according the state’s Attorney General.